HowPROVENGE Targets and Attacks mCRPC*
PROVENGE activates T cells to target and attack prostate cancer cells.
Watch the mechanism of action
Immunotherapy Helps the Immune System Fight Disease
PROVENGE is an autologous cellular immunotherapy designed to activate a patient’s immune system to target and attack prostate cancer cells.
Learn more about PROVENGE as immunotherapy
ShortDuration of PROVENGE Therapy
PROVENGE therapy typically takes about 1 month, and a sustained immune response has been observed out to 26 weeks.
Read about the sustained response of PROVENGE
Manageable Side Effect Profile
Only 1.5% of patients in the pivotal Phase 3 IMPACT Trial discontinued treatment with PROVENGE due to adverse events.
The most common adverse events in PROVENGE trials were chills, fatigue, fever, back pain, nausea, joint ache, and headache.
Learn about safety & side effects of PROVENGE
A brief overview about PROVENGE, its mechanism of action, clinical data, patient selection, and administration
*Metastatic castrate-resistant prostate cancer